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In the current study, we conducted a quantitative in-depth proteome and deglycoproteome 
analysis of cerebrospinal fluid (CSF) from relapsing-remitting multiple sclerosis (RRMS) and 
neurological controls using mass spectrometry and pathway analysis. More than 2000 proteins 
and 1700 deglycopeptides were quantified, with 484 proteins and 180 deglycopeptides 
significantly changed between pools of RRMS and pools of controls. Approximately 300 of 
the significantly changed proteins were assigned to various biological processes, including 
inflammation, extracellular matrix organization, cell adhesion, immune response and neuron 
development. Ninety-six significantly changed deglycopeptides mapped to proteins that were 
not found changed in the global protein study. In addition, four mapped to the proteins oligo-
myelin glycoprotein and noelin, which were found oppositely changed in the global study. 
Both are ligands to the nogo receptor, and the glycosylation of these proteins appears to be 
affected by RRMS. Our study gives the most extensive overview of the RRMS affected 
processes observed from the CSF proteome to date, and the list of differential proteins will 
have great value for selection of biomarker candidates for further verification. 




Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) 
which causes demyelination and axonal damage. The disease affects more than 2 million 
people worldwide and is the most common cause of neurological disability in young adults 
besides trauma 1. The etiology of MS is still unknown, but data implies that susceptibility to 
MS is a combination of genetic and environmental risk factors 2, 3.   
Currently there is no general cure for MS. Multiple disease modifying drugs are 
available (reviewed in 4, 5), but they may be moderately effective and result in serious side 
effects 6-9. In the recent years, hematopoietic stem cell transplantation has emerged as a 
treatment option, but at the moment it is only given to patients with severe and aggressive MS 
10, 11. Novel medication offers new possibilities for individualized treatment, but also raises 
new questions given that the heterogenic nature of MS may complicate the treatment 
decisions. It is therefore critical to understand the nature of the disease and how the disease 
pathogenesis varies between patients. Disease activity and therapeutic efficiency is at present 
measured through relapse rate, magnetic resonance imaging (MRI) outcome, and changes in 
the expanded disability status scale (EDSS) score (reviewed in 4), which all have limited 
sensitivity. New biomarkers for diagnosis, therapeutic response and disease progression are 
therefore needed.  
Cerebrospinal fluid (CSF) is the most commonly used body fluid for studying 
neurological disorders as it reflects ongoing pathological and inflammatory processes related 
to CNS diseases 12. Normally, the blood-brain-barrier (BBB) protects the CNS from entry of 
immune cells, but in MS this protective barrier is disrupted, and this allows for activated 
immune cells to migrate across the BBB. Proteomics has already proven useful for biomarker 
studies in MS, and elevated chitinase-3-like protein 1 (CHI3L1) levels in CSF was suggested 
as a biomarker for disease progression from clinically isolated syndrome (CIS) to clinically 
definite MS (CDMS) 13 as well as a potential biomarker for therapeutic response 14. 
A number of biomarker studies have been published for MS (reviewed in 15), but they 
all present a low number of quantified proteins compared to the number of identified proteins 
in CSF 16, 17. Furthermore, none of these studies provide quantitative information for the 
glycoproteome, which is expected to contain promising biomarkers for various diseases, 
including MS 18-21. In a recent glycoproteome experiment in CSF from neurologically healthy 
patients, more than 500 glycoproteins from over 1,100 deglycopeptides were identified 16, 
indicating that the CSF glycoproteome could be an important source of information for 
monitoring CNS processes.   
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In this study, we present a quantitative in-depth comparison of CSF from RRMS 
patients and neurological controls, with protein quantification data for more than 2,000 
proteins and 1,700 deglycopeptides. This is the most comprehensive quantitative proteomics 
study of the CSF proteome to date, and it provides a new and deeper level of information 
about the pathological processes in RRMS patients reflected in the CSF proteome. 
 
 
EXPERIMENTAL PROCEDURES  
CSF collection and patient information  
CSF was collected from individuals that underwent a diagnostic lumbar puncture (LP) at the 
Department of Neurology, Haukeland University Hospital, Bergen, Norway, according to the 
recommended consensus protocol for CSF collection and biobanking 22. All RRMS patients 
were diagnosed according to the revised McDonald criteria 23 and were diagnosed as RRMS 
at the time of LP. The samples comprised CSF from 21 patients diagnosed with RRMS and 21 
controls with other neurological diseases (OND). The OND controls were evaluated by a 
neurologist to have no risk of developing MS. None of the RRMS patients received 
medication prior to the LP. All RRMS patients had oligoclonal CSF bands (OCB), whilst all 
OND controls were OCB negative. All included CSF samples had to have normal protein 
concentration and cell count. Detailed patient information is shown in Table S1. The study 
was approved by The Regional Committee for Medical Research Ethics of Western Norway. 
Written informed consent was obtained from all patients and controls. 
 
Preparation of pooled samples 
The 42 CSF samples were randomly divided into three pools of RRMS patients and three 
pools of OND controls, using controlled randomization ensuring that one male was in each 
pool, resulting in six pools with seven individuals in each pool (Table S1 and Figure 1A). 
Equalized CSF amounts presenting 200 µg of protein total content from every donor were 
used to create the pools, making the final total protein amount in each pool 1,400 µg. The CSF 
protein concentration was measured using turbidimetry instrumentation (Roche). The total 
protein concentration in each pool is shown in Table 1. The same pools were used for both 
the global proteome analysis and the glycoproteome analysis.  
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Table 1. Summary information on all CSF donors.  
 
 Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 Pool 6 t-test p-
value 
Diagnosis RRMS RRMS RRMS OND OND OND  
n 7 7 7 7 7 7  
Male/female 1/6 1/6 1/6 1/6 1/6 1/6  
Age at LP. 36.4 (7.5) 38.3 (6.7) 35.7 (8.3) 34.1 (9.7) 35.7 (9.2) 36.4 (8.6) 0.5798 


























# months from first symptom to LP 10.6 (22.2) 11.1 (18.4) 9.4 (10.5) N/A N/A N/A  
EDSS score at LP 1.4 (0.79) 1.2 (0.70) 1.2 (1.07) N/A N/A N/A  
OCB positive 100 100* 100 0 0 0  
Total [protein] after depletion 
(µg/µL) 
0.743  0.839 0.953 1.41 1.01 1.30 0.0419 
TMT label  global 
proteome analysis 
126 128 130 127 129 131  
TMT label  
deglycoproteome analysis 
128 130 127 126 129 131  
*One patient was not analyzed for OCB (oligoclonal bands). All data are expressed as mean (SD). 
 
Chemical, reagents and solutions 
Iodoacetamide (IAA), urea, calcium hydrochloride, methylamine, N-Octyl-β-D-
glucopyranoside (NOG), ammonium formate, DTT, sodium periodate and PNGase F enzyme 
were purchased from Sigma Aldrich. Trypsin was purchased from Promega (sequencing 
grade). Affi-Prep® Hz hydrazide support slurry was purchased from Bio-Rad (control 
210011598). Water, ACN, TFA and formic acid (FA) were purchased from Sigma Aldrich 
and were mass spectrometry grade. Tandem-mass-tag (TMT) 6-plex reagents were purchased 
from ThermoFischer Scientific (Lot number OI191932). Solutions for protein depletion were 
purchased from Agilent Technologies.  
  
Sample preparation, protein depletion, protein digestion and TMT labeling  
Global proteome analysis 
A CSF aliquot from each pool (500 µg) was immunodepleted (MARS Hu-14, 4.6 mm x 50 
mm LC column, Agilent Technologies), desalted and concentrated as described previously 24. 
The protein concentration after depletion was measured in each pool using the QubitTM 
fluorometer (Invitrogen) and 30 µg protein from each pool were in-solution digested as 
described in 25, except that trypsin was used in a 1:40 ratio. Each sample was desalted using 
the reverse phase Oasis® HLB µElution Plate 30 µm (Waters), labeled using TMT 6-plex 
reagents as detailed in Table 1, combined according to the manufacturer’s protocol and 
desalted as described in 24. The experimental workflow is illustrated in Figure 1B. The 
labeling efficiency was investigated prior to combining the TMT labeled samples, and showed 




Figure 1. Illustration of the pooling procedure (A) and the workflow of global (B) and deglycoproteome 
(C) experiments performed in this study. The pooling procedure shown in Figure 1A illustrates that 21 
relapsing-remitting multiple sclerosis (RRMS) patients and 21 neurological controls with other neurological 
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diseases (OND) were separated into six pools, with seven individuals in each pool. These pools were used for 
two separate experiments: B) Global proteome analysis and C) Deglycoproteome analysis. Only the global 
experiment included protein depletion (B), while trypsin digestion, TMT labeling and combination of the labeled 
pools was common for both experiments. Glycopeptide capture by solid-phase enrichment of N-linked 
glycopeptides (SPEG) was then performed in the glycoproteome experiment (C), followed by peptide 
fractionation, LC-MS/MS analysis and protein and peptide identification and quantification, which was common 
for both experiments. 
 
Deglycoproteome analysis 
A CSF aliquot from each pool (100 µg) was purified and concentrated using 3 kDa 
ultracentrifugation filters as described in 26, in-solution trypsin digested, desalted and TMT 
labeled as described for the global proteome analysis. Approximately 1.5 μg was taken from 
each sample for testing the labeling efficiency, which was found to be > 99%.  
 
Glycopeptide enrichment 
The samples for the deglycoproteome analysis were combined, concentrated and dissolved in 
300 μL 0.1% TFA and further acidified by addition of 2 μL 100% TFA before a new Oasis® 
HLB desalting, now using a 10 mg plate as previously described 26. The resulting sample was 
then concentrated, oxidized in 10 mM sodium periodate, 0.1% TFA, and desalted by Oasis® 
HLB as in 26. Oasis eluate was added to 50 μL Affi-Prep® Hz hydrazide support slurry, 
prewashed with 1 mL deionized water. Beads and peptides incubated overnight before beads 
were washed and deglycosylated peptides were released by PNGase F digestion, desalted by 
Oasis® HLB µElution and concentrated, as described in 16, 26. Five percent of the sample was 
saved for prefractionation LC tandem mass spectrometry analysis, in case some peptides were 




The TMT labeled peptides were fractionated (100 fractions for the global proteome analysis 
and 15 for the deglycoproteome analysis) using mixed-mode chromatography on a Sielc 
Promix MP column (MP-10.250.0530, 1.0 × 250 mm, 5 μm, 300Å, Sielc Technologies) and 
an Agilent 1260 series LC system (Agilent Technologies). The peptides were reconstituted in 
buffer A (20 mM ammonium formate, 3% ACN) and loaded on the column using 15% buffer 
B (2 mM ammonium formate, 80% ACN, pH 3.0). Details for the gradient and fraction 
collection are in Table S2.  
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Liquid chromatography mass spectrometry analysis 
Each fraction (100 for the global proteome analysis and 15 for the deglycoproteome analysis) 
as well as the prefractionation deglycoproteome sample was freeze dried in a Centrivap 
Concentrator (Labconco) and dissolved in 2% ACN, 1% FA. Approximately 0.5 µg of 
peptides from each fraction was injected into an Ultimate 3000 RSLC system (Thermo 
Scientific) connected to a Q-Exactive HF equipped with an EASY-spray ion source (Thermo 
Scientific). The samples were loaded and desalted on a pre-column (Acclaim PepMap 100, 2 
cm x 75 µm i.d. nanoViper column, packed with 3 µm C18 beads) at a flow rate of 3 µL/min 
for 5 min with 0.1% TFA. The peptides were separated during a biphasic ACN gradient from 
two nanoflow UPLC pumps (flow rate of 0.200 µL/min) on a 50 cm analytical column 
(PepMap RSLC, 50 cm x 75 µm i.d. EASY-spray column, packed with 2 µm C18 beads 
(Thermo Scientific). Solvent A was 0.1% FA in water and Solvent B was 100% ACN. The 
fractions were applied different LC-methods depending on their elution time from the mixed-
mode column (Table S3). For the deglycoproteome experiment, all fractions were initially 
analyzed using one LC-gradient. Additionally, since peptides in fractions 7-15 eluted very late 
in the gradient, those fractions were reanalyzed using a longer (105 min) gradient (Table S3). 
The mass spectrometer was operated in data-dependent acquisition mode to 
automatically switch between full scan MS1 and MS2 acquisition. The instrument was 
controlled through Q Excative HF Tune 2.4 and Xcalibur 3.0. Mass spectrometry spectra were 
acquired in the scan range 375-1500 m/z with resolution 60,000 at m/z 200, automatic gain 
control (AGC) target of 3e6 and a maximum injection time (IT) of 50 ms. The 12 most intense 
eluting peptides above intensity threshold 6e4, and charge states two or higher, were 
sequentially isolated for higher energy collision dissociation (HCD) fragmentation and MS2 
acquisition to a normalized HCD collision energy of 32%, target AGC value of 1e5, 
resolution R = 60,000, and IT of 110 ms. The precursor isolation window was set to 1.6 m/z 
with an isolation offset of 0.3 and a dynamic exclusion of 30 seconds. Lock-mass (445.12003 
m/z) internal calibration was used 27 and isotope exclusion was on. 
 
Data Interpretation   
Global proteome analysis 
All raw files were converted to mgf using Proteowizard 28 and searched using X!Tandem 29, 
MyriMatch 30, and Comet 31 via SearchGUI (v. 2.8.5) 32 against the Homo Sapiens 
complement of the UniProt/SwissProt reviewed database downloaded April 2016 (20,200 
entries) 33. All non-human contaminant proteins from the Global Proteome Machine cRAP 
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protein sequences (ftp://ftp.thegpm.org/fasta/cRAP/) were added to the downloaded database 
as well as a reversed version of every sequence as decoys. The search settings were: 
carbamidomethylation of C, TMT-6plex labeling on K and N-terminal as fixed modifications; 
oxidation of M as variable modification; trypsin as enzyme with a maximum of 2 missed 
cleavages; precursor charge 2-5; peptide length 6-30; precursor and fragment mass tolerance 
10 ppm. All other settings were left to default.  
The search engine results were combined and assembled in PeptideShaker 34 (v. 
1.10.2). Notably, protein ambiguity groups were made to account for the presence of shared 
peptides between protein sequences 35, and all hits were thresholded to retain only the best 
scoring until reaching a false discovery rate (FDR) of 1% estimated using the distribution of 
target and decoy hits 36. Throughout the manuscript, peptides and proteins refer to peptides 
and protein groups validated at 1% FDR. The default quality control filters of PeptideShaker 
were used and the peptides and proteins passing this additional quality control are referred to 
in the following as confidently identified. The confidence in the localization of 
posttranslational modifications was evaluated using the D-score 37 and PhosphoRS 38 using 
the default settings of PeptideShaker. 
Peptides and proteins were quantified according to 39 using Reporter 
(http://compomics.github.io/projects/reporter.html) (v. 0.3.4) and default settings. Briefly, the 
reporter ion intensities were deisotoped using the purity coefficients provided by the 
manufacturer. For every peptide, abundance ratios were estimated from the aggregation of 
spectrum level ratios using all fractions. In every channel, the peptide ratio estimation was 
done using robust estimators: the median was used if less than six ratios were found, a 
redescending M-estimator elsewise. Using the median or averages of channels has been 
demonstrated to be preferable over using one reference pool 40. Peptide ratios were 
normalized to the median of those peptides that were derived from  the list of brain specific 
proteins presented by Aasebø et al. 24 as suggested as the best way for normalization of CSF 
quantitative proteomics 41. Protein group ratios were finally estimated from peptide ratios 
using the same estimators. For every TMT channel, proteins ratios were normalized to the 
median of the stable proteins as done for the peptides. All human keratins, proteins targeted 
by the depletion column, contaminants and proteins that did not have quantitative values in all 
TMT channels were removed from the dataset (n = 89). The remaining 2,877 proteins were 
included for statistical analysis after logarithm base two transformation. An F-test was used to 
investigate equality of variances between the patients and controls, and a Student’s t-test with 
unequal variances was used when the F-test was significant (p < 0.05) (n = 174). A Student’s 
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t-test with equal variances was used otherwise. The Benjamini-Hochberg correction was used 
as multiple hypothesis test. We further calculated a Z-score to identify most prominent fold 
change (FC) differences between the two groups (RRMS and OND). The FC was calculated 
based on the difference of averages. Proteins with doubtful validation status were removed, in 
addition to removing proteins with fewer than two validated and unique peptides. The 
remaining 2,072 proteins are referred to  as quantified. A p-value < 0.05 from the t-test was 
considered as significant, and the 484 statistically significant proteins were included for 
network analysis and GO-enrichment.   
 
Deglycoproteome analysis 
All raw files (n = 25: 15 fractions + 9 re-runs of late eluting fractions + 1 prefractionation 
sample) were identified and quantified as described above except deamidation of N was added 
as variable modification. A peptide list containing the normalized ratios was exported from 
Reporter and further data processing was performed in Excel. Contaminant peptides were 
removed as well as peptides with no quantitative value in at least one of the TMT channels. 
Adequate routine quantitative methods for the high throughput analysis of glycopeptides, 
comprising both the amino acid backbone and the glycan moiety, are currently not available 
Instead, glycans are usually detached proteolytically after enrichment as detailed above, and 
the remaining amino acid sequence is used as surrogate to estimate the abundance of the 
glycopeptide 42. For this, those identified peptides that present a deamidation at an N-
glycosylation sequence motif [N][XPˆ][ST] (where XP^ can be any amino acid except 
proline) are assumed to be the result of a deglycosylation event.. Deglycopeptides were 




) 𝑥 100. Briefly, a deglycopeptide was defined as a peptide containing a 
deamidation and the N-glycosylation sequence motif, and where a deamidation was not 
confidently assigned only to an asparagine outside the motif. Hence, for peptides with the N- 
glycosylation motif and additional asparagines in the sequence but uncertainty in the 
localization of the deamidation, it was assumed that the deamidation was at the asparagine in 
the motif as a result of the activity of the PNGase F enzyme. This is based on our calculated 
low chance of a non-glycopeptide having both a deamidation and the N-glycosylation motif 
(calculated to be 0.7%) and the fact that N-glycopeptide enrichment had been performed. 
Briefly, to get an idea of the false glycosite identification rate, we performed an additional 
search of the corresponding global data with deamidation of asparagine as a variable 
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modification. Using this dataset we found that the chances of a deamidation occurring in a 
peptide containing the N-glycosylation sequence motif was about 0.7%. Deglycopeptides that 
had at least one deamidation confidently localized on an asparagine in the N-glycosylation 
motif were termed high confident deglycopeptides. Those peptides where the localization was 
doubtful or random, indicating that the scoring algorithms could not confidently assess the 
exact position of the deamidation, were termed medium confident deglycopeptides, although it 
is likely that the deamidation is on the asparagine in the motif, because of the enrichment 
performed. Only 23 of the 2,153 peptides identified in the glycopeptide enrichment 
experiment included both a deamidation and the N-glycosylation motif, where the 
deamidation(s) was confidently assigned only to asparagine(s) outside the motif. These 
peptides were not considered deglycopeptides. 
Significant differences in peptide ratios between patients and controls were identified 
using a Student’s t-test as described for the global proteome. Furthermore, significant peptides 
(p < 0.05) were thoroughly investigated to see if other variants of the peptide were also 
present in the dataset, due to miscleavages or other combinations of modifications on the 
peptide (oxidized M, deamidation of N, etc.), and if they had similar or opposite regulation 
(further described in the Supplemental Information). Deglycopeptide FC abundance 
differences were then compared to the global proteome experiment to identify similar and 
different regulations revealed by the two approaches.  
 
Sharing of data through PRIDE 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium 43 via the PRIDE 44 partner repository with the dataset identifier PXD004572 for 
the global data and PXD004540 for the glycoproteome data. 
 
Protein network analysis  
All of the 484 significantly different proteins from the global proteome analysis were 
imported into STRING 45 with interaction sources being experiments and databases, and the 
interaction score set to medium confidence. The three proteins Ig kappa chain C region, 
semaphorin-3B, and neurofilament light polypeptide (NFL) were not imported as STRING 
could not “detect any proteins by the name in Homo sapiens”. The STRING network was 
exported to Cytoscape v.3.3.0 46. The Cytoscape plugins BINGO 47 ClusterONE 48 were used 
for visualization of the STRING network and cluster analysis. In the cluster analysis, a 
minimum of five proteins was used for network size and interaction evidence towards the 
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combined score from STRING. All other settings were left to default. The Cytoscape plugins 
ClueGo 49 and CluePedia 50 were used for Gene Ontology (GO) analysis of biological 
processes (Homo sapiens GO updated 14.06.16). GO-term fusion and “show pathways with p-
value < 0.05” were activated. Evidence was set to “All without inferred from electronic 
annotation (IEA)” and the network specificity was medium. In the ClueGO analysis, all 
proteins significantly increased in the RRMS patients were analyzed as one group (named 
Cluster 1 by ClueGO) and the proteins significantly decreased in the RRMS patients were 
analyzed as a second group (named Cluster 2 by ClueGO). These two clusters were compared 
by ClueGO, and resulted in two pie charts of biological processes. One pie chart showed the 
enrichment of genes increased in RRMS (Cluster 1) and the other pie chart showed the 
enrichment of genes decreased in RRMS (Cluster 2). A corresponding GO term table was also 
generated presenting the genes behind each term. All other settings were left to default. GO 
analysis with ClueGO and CluePedia was also done for the glycoproteome using similar 
settings.  
 
Comparing significant proteins against relevant literature data 
In order to compare our protein quantification data against relevant and comparable literature, 
we thoroughly investigated previously published quantitative CSF proteome datasets 
presenting biomarkers for MS, Parkinson’s disease (PD) and Alzheimer’s disease (AD) 13, 14, 
25, 41, 51-63. These data were included in an extended version (unpublished) of CSF-PR 16 which 
was used for the comparison. Detailed inclusion criteria for these 17 publications are available 
in the Supplemental Information. To further compare in more detail our 484 significantly 
changed proteins, we extracted quantitative data from those studies comparing RRMS, CIS 
with conversion to MS or CDMS (collectively called MS) to OND, symptomatic controls or 
non-MS (collectively called Non-MS). These particular disease groups were chosen because 
they were similar to the RRMS and control groups used in our study. Eight of the 17 
publications included such comparisons 13, 25, 41, 51, 53-56. Details on the categorization of the 




In this study, pooled CSF was used to analyze the global proteome and deglycoproteome from 
RRMS patients and controls (n = 21 pooled in three RRMS and 3 control pools) as illustrated 
in Figure 1A. We identified 2,966 and quantified 2,072 proteins in the global proteome 
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analysis (Table S4) and in the deglycoproteome analysis 1,744 deglycopeptides mapping to 
697 proteins groups were quantified (Table S5, C). STRING 45 analysis and the Cytoscape 46 
plugin ClusterONE 48 was used for cluster analysis, while the Cytoscape plugins ClueGO 49 
and CluePedia 50 were used for GO-enrichment analysis, as described in the Experimental 
Procedures. 
 
Global proteome analysis 
In the global proteome analysis, we quantified 2,072 proteins with ≥ 2 validated and unique 
peptides. A Student’s t-test was used for statistical analysis and revealed 484 proteins with a 
p-value < 0.05 between the RRMS patients and the controls of which 243 were increased and 
241 were decreased in the RRMS patients (Table S6, A). The 2,072 quantified proteins were 
compared to 17 previously published studies as explained in the materials and methods, and 
quantitative information had not been reported for 1,273 of them. Of the 484 significantly 
changed proteins 236 (49%) had not been quantified in any of the 17 studies, whereas 248 
(51%) had.   
We further compared the 484 significantly changed proteins to the regulations of these 
proteins found in eight other studies analyzing patient groups similar to ours 13, 25, 41, 51, 53-56. 
Of the 248 proteins found in all 17 studies, 216 were quantified in these eight studies and we 
divided the 216 hits into five categories based on their correlation with the literature data. 
More information about this categorization is in Supplemental Information. As can be seen 
from Figure 2, 10 of the proteins significantly increased in MS were also reported with 
increased abundance in the eight comparable studies (Increased 100%). Seventeen proteins 
fell into the “Increased < 100%” category, indicating that these proteins were found 
significantly increased in MS in the majority (average) of the studies. The numbers for the 
proteins significantly decreased in MS were 10 (Decreased 100%) and 50 (Decreased < 
100%). For the remaining proteins (129), their abundance had been reported with either 
opposite significant change (9 proteins) or an average non-significant change (Equal, 120 




Figure 2: Distribution of protein data for proteins previously quantified in comparable CSF studies. 
Proteins found significantly increased (left) or decreased (right) in RRMS were compared separately to eight 
publications. Red circles represent the query proteins found increased in MS compared to Non-MS in 100% of 
the studies and pink circles represent the proteins found increased in MS in the majority of studies, but with 
some conflicting data. Green and light green circles represent these same trends for the decreased proteins. The 
blue circles represent the proteins found unaltered between MS and Non-MS on average in the seven studies.  
The MS category is a combination of the reported MS subcategories: RRMS,  CDMS and CIS with conversion to 
MS, and the Non-MS category is a combination of the control group subcategories reported as OND, 
Symptomatic controls and Non-MS. More information about this categorization is in Supplemental 
Information. *Combined categories 
 
Deglycoproteome analysis 
Glycopeptide identification and quantification 
In total 2,153 peptides mapping to 734 protein groups were quantified from the glycopeptide 
enrichment experiment (Table S5, B) of which 1,744 (Table S5, C) were identified as 
deglycopeptides (Experimental Procedures) mapping to 697 glycoproteins. This gave a 
peptide enrichment specificity of 81%. Of these, 1617 were high confident deglycopeptides 
(Table S5, D) and 127 medium confident (data not shown). Furthermore, 153 (< 10%) of the 
deglycopeptide sequences were also identified in the global peptide dataset, when comparing 
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against 32,701 confidently validated peptides quantified in all six pools (Table S5, H). This 
shows that both a glycosylated and non-glycosylated form of these proteins is likely to exist.  
We retrieved Uniprot glycosylation annotation data for all the proteins to which our 
glycopeptides mapped and checked our identified sites (only sites on unique peptides and 
where there was only one possible glycosylation site) against all known sites for these 
proteins. Information about referenced glycosylation status on both protein and site level can 
be found in Table S5, sheet C. In summary, we identified a total of 1,239 unambiguous 
glycosylation sites, of which 515 were already referenced in Uniprot and 724 were new. In 
addition, sites on 62 peptides were termed ambiguous either because they were on non-unique 
peptides or because there were two possible glycosylation sites. Previously undocumented 
glycosylation data is here demonstrated (indirectly as deglycopeptides) for 304 proteins. 
 
Categorization of significant deglycopeptides 
Of the quantified deglycopeptides, 235 were found to have significant differences between 
MS and OND (Table S5, E). These were manually inspected to reveal if other peptide 
variants containing the same glycosylation site had conflicting relative abundances in the 
deglycoproteome dataset. Different peptide variants containing the same glycosylation site 
could be non-tryptic peptides or appear due to missed cleavages and/or modifications (see 
Supplemental Information for details). This manual validation resulted in 180 non-
conflicting significantly changed deglycopeptides (Table S5, G) which were used as input for 
GO enrichment analysis in Cytoscape. Furthermore, 49 of these deglycopeptides also had a 
significant z-score based on the observed FC (Table S7), and represent the deglycopeptides 
most likely to be changed in RRMS compared to controls. 
 
Global versus deglycoproteomics experiments 
We further compared the deglycopeptide and the global protein FC (log2) for the 180 non-
conflicting deglycopeptides (Table S8, B). Four deglycopeptides substantially deviated from 
their protein FC with significant opposite regulation. These peptides derive from oligo-myelin 
glycoprotein (OMgp) (three peptides, negative FC) and noelin (one peptide, positive FC). 
OMgp was found significantly increased (p < 0.01) in RRMS patients in the global study by 
22 peptides, whereas in the deglycoproteome study, all three quantified deglycopeptides were 
found significantly decreased (p < 0.05). Noelin, on the other hand, was significantly 
decreased (p < 0.005) in the global data, but was found with a significantly increased (p < 
0.05) peptide in the deglycoproteome study. More details on these data are available in Table 
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S8, A, B. We also plotted the FC difference between  all 1,744 quantified deglycopeptides and  
all quantified global proteins, and it was clear that most deglycopeptides display a FC similar 
to the protein FC from the global experiment (Table S8, C, D). 
 To assess the possibility of identifying glycoproteins in CSF without glyco enrichment 
procedures, we investigated the known glycosylation status of the 2,072 proteins quantified in 
the global CSF study, and found that 580 of these were annotated with one or more referenced 
glycosylation sites in Uniprot. We further compared these to the proteins to which our 
quantified deglycopeptides mapped. We found that 249 of them were not found in the 
deglycoproteome experiment, meaning that these proteins could only be identified using the 
global proteome approach. Information about which proteins have referenced Uniprot 
glycosylation status and whether they were also found in the deglycoproteome experiment can 
be found in Table S4, B. 
 
GO enrichment analysis of significantly changed proteins and glycoproteins 
The Cytoscape plugins ClueGO 49 and CluePedia 50 were used for GO enrichment analysis for 
comparing which biological processes that were enriched in the RRMS patients, as described 
in the Experimental Procedures. For the global data, the 484 significant proteins (mapping to 
319 unique genes in ClueGO, Table S9) were imported, while the 180 non-conflicting 
significantly changed deglycopeptides (mapping to 138 proteins and 85 unique genes in 
ClueGO, Table S5, G and Table S10) were imported for the glycoproteome analysis. The 
processes that were enriched in proteins significantly increased in RRMS patients are 
illustrated in Figure 3 A and B, and the processes enriched in proteins significantly decreased 
in RRMS patients are illustrated in Figure 3 C and D. Each pie chart is divided into different 
groups, named according to the leading term for each group. The group leading term was 
chosen by ClueGO and depends on e.g. the number of genes, percentages of found genes and 
the p-value for the different terms. All data for Figure 3 A and C (global proteome) can be 






Figure 3. Biological processes GO enriched in proteins increased (A and B) and decreased (C and D) in CSF of RRMS patients. The global data is shown in A 




As shown in Figure 3 A and B, the processes enriched in proteins increased in RRMS 
patients relate to the inflammatory response, such as protein processing, protein activation 
cascade, leukocyte migration, acute inflammatory response and defense response. Further, the 
enriched processes included proteins involved in extracellular matrix (ECM) organization, 
aminoglycan and chitin metabolic processes, and coagulation. Of the processes that were 
enriched in proteins decreased in RRMS patients (Figure 3, C and D) we found neuron 
development, including axonal development and cell morphogenesis involved in neuron 
differentiation, fibril-organization, and chemotaxis.  
 
Global proteome interaction analysis of significantly different proteins 
The 484 significantly changed proteins (Table S6) were imported into STRING 45 and 
interactions were found between 222 of the imported proteins. The protein-protein interaction 
(PPI) network was further exported to Cytoscape 46 and the main network (170 genes) is 
visualized in Figure 4. The two proteins amyloid-beta A4 protein (APP) and epidermal 
growth factor receptor (EGFR) represented the key nodes (genes) with the highest number of 
interactions in the PPI network. The EGFR pathway has been indicated to contribute to the 
inflammation amplifier 64. Other studies have indicated that inhibition of EGFR protects 
neurons from degradation and is neuroprotective in rat models of both spinal cord injury 65 
and glaucoma 66. For APP, a wide range of functions have been suggested in the CNS 67, but it 






Figure 4. Protein-protein interaction (PPI) network. 484 significantly changed proteins between the RRMS 
patients and the controls (Table S6) were imported into STRING 45 and interactions were found between 222 of 
the 484 proteins. The PPI was visualized in Cytoscape v3.3.0. Green and red colors represent lower and higher 
expression of proteins in CSF between RRMS patients and controls, respectively. Light green and light red 
represent proteins with z-score significance > 0.05, while the dark green and red proteins have z-score 
significance < 0.05. Rectangles are proteins with a t-test p-value < 0.01, while the proteins represented by a 




The Cytoscape plugin ClusterONE reported 14 clusters with a p-value < 0.05 (Figure S1) 
using the PPI network from Figure 4 as input. A selection of the most significant clusters 
containing five or more genes is shown in Figure 5A-F. These clusters contain (a) cadherins, 
involved in cell adhesion, (b) collagens, which are ECM proteins, (c) complement factors, 
involved in inflammation, (d) ephrins and other proteins involved in synaptic plasticity, (e) 




Figure 5. Cluster analysis of the protein-protein interaction network using ClusterONE. A minimum of 
five genes was included in the network and interaction evidence towards the combined score from STRING. a) 
cadherins b) collagens c) complement proteins d) ephrins and proteins involved in synaptic plasticity e) proteins 
involved in aminoglycan processes f) proteins involved in the coagulation and inflammation. Green and red 
colors represent lower and higher expression of proteins in CSF between RRMS patients and controls, 
respectively. Light green and light red represent proteins with z-score significance > 0.05, while the dark green 
and red proteins have z-score significance < 0.05. Rectangles are proteins with a t-test p-value < 0.01 while the 






In the present study, we compared the CSF global and glycoproteome between RRMS 
patients and controls using TMT-labeling, extensive peptide fractionation, and state of the art 
bioinformatics. More than 2,000 proteins and 1,700 deglycopeptides were identified and 
relatively quantified with high confidence, and we hereby present the most comprehensive 
quantitative CSF proteomics study to date.  
The pooling strategy undertaken in our study allows us go deep into the CSF proteome 
to reveal novel information about how RRMS affects the CSF proteome. When pooling 
samples, information about biological variation between individuals is lost, but other studies 
have shown no systematic bias due to pooling 69 as well as agreement between the protein 
expression in pools and the mean of individual samples 70. This is in accordance with our own 
observations when comparing our pooling data to previously published work and we therefore 
conclude that the observed protein regulations in general are in concordance with the mean 
measurements of the individuals. Based on this the pooling strategy was considered as a 
suitable approach particularly since our study is focused on the processes affected by MS at 
large and not on finding single biomarker candidates. 
Our study provides additional evidence for differential expression of previously 
discovered biomarker candidates, in addition to novel findings. The fact that 236 of the 484 
proteins found as significantly changed have not been quantified in any of the 17 recent 
publications we compared our data to shows that our data revealed regulations occurring in a 
deeper part of the proteome not previously studied. CHI3L1, CHI3L2 and NFL are among the 
few proposed biomarkers that have previously been confirmed to be affected by MS 13, 53, 71-73. 
We found these proteins significantly changed in agreement with the literature, demonstrating 
how CSF quantitative proteomics can reliably and reproducibly detect significant changes 
associated with neurological disorders. In addition, 87 of our significantly different proteins 
have previously been found with similar regulation in other studies (Figure 2). This shows 
that the pooling strategy used here provides reliable quantitative information. 
Since LP is an invasive procedure, it is important to investigate the possibility to 
observe significant CSF changes also in serum or plasma. This has been done in some studies 
13, 53, 54, 74, attempting to verify biomarker candidates found in CSF. Some of the most studied 
proteins in CSF and serum are CHI3L1, CHI3L2 and NFL 13, 53, 74, 75. Significant increase of 
CHI3L1 have been found in serum of CIS and RRMS patients compared to non-inflammatory 
neurological controls 53, but increased CSF CHI3L2 levels found in RRMS compared to CIS 
and non-inflammatory neurological controls were not confirmed in serum 53. Others have also 
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investigated the effect of treatment on CHI3L1, and a trend towards decrease in the plasma 
CHI3L1 levels after treatment with INFβ has been observed 74. This shows that the CHI3L1 
levels between CSF and plasma/serum correlate, but the CHI3L2 levels do not. This offers 
new possibilities for easier diagnosis and estimation of disease progression and treatment 
effect. Studies have also investigated other candidate proteins in serum of MS patients 13, 54, 
but these have found no change between MS subtypes and controls.  
To investigate the chance of sampling our 484 significantly changed proteins in blood, 
we compared them to CSF-PR 16 and the Plasma Proteome Database 76. We found that 80% of 
our significantly changed proteins were previously found in plasma or serum, and the 
remaining proteins were not found (Table S6), indicating that they are likely difficult to 
measure in a blood sample. The list of changed proteins will be a valuable source for selecting 
new biomarker candidates for MS for further validation. In addition, the deep coverage of the 
CSF proteome gave us a unique possibility to obtain a broader overview of the RRMS 
affected processes that can be monitored via the CSF proteome.  
 
Cluster analysis and GO enrichment 
Inflammation and the immune system 
MS is known as an inflammatory disease, and the increase of proteins and pathways related to 
the immune- and complement system in RRMS are therefore not surprising. A characteristic 
of the MS brain is the presence of lesions or plaques infiltrated by immune cells, such as T-
cells and macrophages 77 which are cells involved in both the innate (native) and adaptive 
(acquired) immune system. The innate immune system acts in a non-specific manner and has 
no memory. Contrary, the adaptive immune system has specificity against certain molecules 
and among others includes CD4+ T-helper cells and CD8+ cytotoxic T-cells (reviewed in 78).  
The BBB normally protects the CNS from entry of immune cells, but in MS this 
protective barrier is disrupted, allowing for activated immune cells to migrate across the BBB 
(reviewed in 79). Why this disruption occurs and how the immune cells enter the CNS is not 
fully understood, but can hold the key for novel MS treatment. The cells from the innate and 
adaptive immune system has the ability to produce chemokines, cytokines and other 
inflammatory factors, which will continue to recruit immune cells into the CNS during the 
inflammatory event. In accordance with theory, we see an enrichment of proteins significantly 
increased in RRMS in the GO term leukocyte migration. We do however also see an 
enrichment of proteins significantly decreased in RRMS in the GO terms chemotaxis and 
regulation of chemotaxis. Chemokines have the ability to influence the movement of immune 
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cells by chemotaxis, attracting them towards a higher concentration of chemokines 80. Our 
data may imply that the response to such chemical stimuli is impaired in the RRMS patients. 
This could perhaps be a result of blockage of chemokine receptors on the immune cells, 
resulting in disturbance of leukocyte movement.  
Increased activity of the adaptive immune system, characterized by release of 
immunoglobulins (Igs), more known as antibodies, is already a well-established trait in 
RRMS. In our data, we found multiple Ig deglycopeptides increased in the RRMS patients. 
However, Igs of the adaptive immune system were not found in the global data, due to the 
removal of IgG, IgM and IgA using protein depletion. We further found increase of the 
complement proteins C6-C8 (Figure 5C), members of the innate immune system that are 
involved in the generation of the membrane attack complex. Three proteins belonging to the 
C1-complex, part of the classical complement pathway, were also found increased in these 
data (Figure 4). It has previously been suggested that antibody and complement mediated 
phagocytosis is involved in the demyelination seen in MS 81. 
Furthermore, our GO analysis showed enrichment of proteins increased in RRMS 
related to the coagulation cascade in MS. This was also seen in the cluster analysis (Figure 
5F), and has also been found by others 82, 83. In a study investigating pathways for MS 
subtypes, the complement and coagulation cascades were demonstrated as a shared pathway 
for all MS subtypes 82. In addition, Han et al. profiled the MS lesion specific proteome and 
uniquely identified several coagulation proteins in chronic active plaques, suggesting a 
dysregulation of molecules associated with coagulation in MS 83. In the same study, 
coagulation cascade inhibitors were demonstrated to suppress Th1 and Th17 cytokines in 
astrocytes and immune cells and to decrease disease severity in an experimental autoimmune 
encephalomyelitis model. This point towards a role for coagulation cascade participants as 
potential therapeutic targets 83. The coagulation proteins we find as increased in CSF could 
very well appear due to these MS-related CNS processes. The GO analysis also showed an 
enrichment of proteins increased in platelet degranulation. Platelets have been found to be 
activated in MS 84 and they are known to alert the immune system during a coagulation 
process. They may therefore have important roles in the regulation of the innate and adaptive 
immune processes seen in MS, as they also secrete pro-inflammatory molecules 85, 86. 
 
Extracellular matrix organization 
ECM organization was also found as a biological process enriched in RRMS from the GO 
analysis, and this is also supported by the cluster analysis demonstrating an increase of 
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collagens. Collagens are important fibrous ECM proteins 87 and mainly appear in the ECM as 
fibrillar proteins to form various connective tissues 88. We also see that deglycopeptides from 
ECM proteins such as fibronectin domain containing proteins, vitronectin and 
thrombospondin, demonstrate a significant change in RRMS compared to controls. In the 
brain, ECM proteins not only provide support and structure, but can also have various roles in 
the development and maturation of neurons 89. The growth and elongation of many neurons is 
directed through the ECM and it is therefore not surprising that ECM structures and 
interactions can influence developing neurons 90. ECM signaling and recognition are also 
important in the migration of leukocytes into inflammatory sites and their entry through blood 
vessels 91. It has been suggested that the BBB breakdown occurring in MS causes ECM 
alterations and that deposition of ECM components in active lesions can contribute to disease 
progression 92. ECM proteins such as fibrillar collagens have previously been found 
upregulated in both active and inactive MS lesions 89, and altered expression of collagen has 
been found in internal jugular veins of MS patients, supporting a role of a vascular 
involvement in MS 93. 
Other ECM proteins highlighted in our cluster (Figure 5E) and GO analyses 
(aminoglycan metabolic processes) (Figure 3) are the proteoglycans (PGs), which are 
macromolecules of the ECM and cell surface. The PGs in our data bears either heparan sulfate 
or chondroitin 94 and appears in cluster with sulfotransferases. Although PGs are known to 
have a role in relation to astroglial scarring and axon regrowth after injury 95, 96, few studies 
have discussed PGs specifically in relation to MS. However, Sobel and colleagues 
investigated active MS lesions and conclude that white matter ECM PG changes in MS 
happens in the early inflammatory phases and contribute to failed axonal regrowth and repair 
97. From our analysis it seems clear that alterations in heparan sulfate, chondroitin, and 
chondroitin sulfate PGs are occurring in RRMS, and we hypothesize that this could be related 
to the transfer of sulfo groups, based on the many sulfotransferases that interact with the PGs, 
as shown in Figure 5E. The aminoglycan processes also include proteins related to chitin 
catabolic processes (Table S9). CHI3L1 and CHI3L2, chitinase domain-containing protein 1, 
chitotriosidase-1 and Di-N-acetylchitobiase were found increased in the RRMS patients. Of 
these proteins, CHI3L1 and 2 lack chitinase activity and have been widely studied in relation 






Neuron development  
We found an enrichment of proteins significantly decreased in RRMS in the GO terms axon 
development, neuron cell-cell adhesion, neuron recognition, and cell morphogenesis involved 
in neuron differentiation (Figure 3C and D, Table S9, cluster 2 and Table S10, cluster 2). 
These categories indicate an impaired development and morphogenesis of neurons, especially 
with respect to axon development. Neurodegeneration and axonal damage are proposed to be 
primary mechanisms behind permanent disability in MS 98, and our data support the presence 
of such processes. Cerebral axonal damage has been demonstrated in early stages of MS, and 
transected axons, neurons, and apoptotic neurons have been found in MS lesions 99, 100. In 
general, the observation of reduced levels of proteins related to neuron development is likely 
due to an impaired ability in MS patients for neuronal repair after inflammatory damage, or 
simply a reduced ability to obtain a normal maintenance/turnover of neuronal cells. It would 
be highly relevant to investigate further the proteins represented in the GO terms mentioned 
above, to evaluate their potential as therapeutic targets to reduce neurodegeneration in MS, as 
the current treatment is so far mainly targeting the inflammatory aspect of the disease. A study 
has shown that the CSF levels of the axonal marker NFL is reduced due to natalizumab 
treatment, and may have an impact to reduce axonal loss 101. However, treatment with 
natalizumab may also have serious side effects. Our supplied list of gene names linked to 
various GO terms (Table S9), e.g. those under the GO terms related to neuron development, 
can  provide useful background data to guide future studies investigating new potential 
treatments targeting neurodegeneration. 
Many of the proteins found related to neuron development are ephrin and ephrin 
receptor proteins which are also highlighted in the cluster analysis (Figure 5D). Ephrin 
proteins are ligands for the ephrin transmembrane tyrosine kinase receptors and this ligand-
receptor signaling has already been linked to the regulation of axonal guidance through the 
regulation of growth cones 100 and to myelination, as mediators of the signaling between 
axons and oligodendrocytes 102. It seems that this signaling can either stimulate or repulse 
axon growth, and the ephrins may well also be therapeutic targets in MS 103.  
Among the 165 proteins not mapped to a gene during the GO analysis (Table S6), we 
find multiple proteins with a potential role in the nervous system. Some of these proteins 
showed significant interactions in the cluster analysis (Figure 3D), and are among other 






Several adhesion molecules were also found decreased in RRMS patients compared to 
controls in both the global and deglycopeptide datasets, such as the cadherins (Figure 5A) 
and several protocadherin deglycopeptides. Cadherins are transmembrane glycoproteins 
known for their role in cell adhesion, especially in tissues, where they help maintain a 
multicellular structure 105. N-cadherin has previously been linked to de- and remyelination 
using mouse models 106, 107. They are further involved in the recruitment and migration of 
neural progenitor cells into MS lesions and are a key element in promoting repair 106. Other 
cell adhesion molecules, including neurexins, neuroligin, integrins and immunoglobulin 
superfamily molecules, have been found significantly changed in our study, highlighting a 
possible role of these proteins in MS. A gene pathway study from 2014 links cellular adhesion 
molecules to MS susceptibility and point to their role in T-cell BBB crossing, which is an 
important event in the MS pathology 108, 109. It may well be that the decrease in adhesion 
molecules are, in fact, also directly linked to the neurodegeneration seen in MS, as their 
important role in organization and maintenance of tissue structure could be disturbed in 
affected individuals. Figure 3C specifically highlight proteins under the GO terms neuron 
cell-cell adhesion as decreased in RRMS, supporting this theory. These decreased proteins 
could therefore also be relevant to investigate further with the aim of targeting the 
neurodegenerative manifestation of MS. 
 
Cerebrospinal fluid glycosylation data 
In comparison with the existing literature on glycopeptides and proteins in CSF, we have by 
far identified and quantified the highest number of glycopeptides or deglycopeptides to date. 
In 2006, Pan et al. identified 216 O- and N-linked glycoproteins by a combination of lectin 
affinity and hydrazide chemistry in addition to 103 non annotated  proteins (glycosylation not 
annotated or protein not in Pubmed) 110. Furthermore, other studies of glycosylation in CSF 
include a study by Nilsson et al. from 2009 identifying 36 N-linked and 44 O-linked 
glycosylation sites in CSF 111, one by Halim et al. from 2012 reporting 84 O-linked intact 
glycopeptides 112 and one from Goyallon et al. from 2015 reporting 124 intact glycopeptides, 
covering 55 glycosylation sites in 36 proteins 113. However, the previously most 
comprehensive characterization of glycosylation in CSF was published by our group in 2014, 
where we reported 1121 previously glycosylated peptides after PNGase F treatment, and they 
mapped to 520 proteins 16. In comparison with referenced glycosylation data in Uniprot, our 
new data here indirectly demonstrates glycosylation sites for 304 proteins previously not 
27 
 
annotated as glycosylated, however it should be stressed that this data should be further 
verified by direct identification of the intact glycopeptide. 
Our assessment of the Uniprot glycosylation status of all quantified proteins in the 
global experiment revealed that 580 of these were referenced glycoproteins, and furthermore 
that 249 of these were not found by our glycopeptide enrichment approach (Table S4, B). 
Since this global experiment gives no information about glycosylation status it may well be 
that these proteins are simply not glycosylated in CSF, although found glycosylated in other 
tissues or body fluids (Uniprot). Other reasons for not identifying them in our 
deglycoproteome experiment might be that they mainly contained O-linked glycosylation 
sites, which were not targeted by our approach, or that the specific glycosylated peptides also 
contained additional modifications not considered in our search settings. Finally, the reason 
may also be that we did not reach the same depth in the deglycoproteome experiment as in the 
global (depletion and 100 fractions in global vs. no depletion and 15 fractions in glyco). 
 
Comparing significant deglycopeptides to the global proteome data 
Many of the significant deglycopeptides demonstrated the same significant changes as their 
corresponding global protein (Table S5, G). However, 96 significantly changed 
deglycopeptides without corresponding global change were also found (Table S5, G). These 
are likely to come from CSF proteins that are present in both glycosylated and non-
glycosylated form, where only the glycosylated form is affected by the disease. They 
represent an interesting set of potential disease altered glycoproteins, where changes might be 
associated with glycosylation events.  
The same is true for the even more interesting four deglycopeptides with opposite 
significant changes compared to the global protein. In these cases, MS might have affected the 
two protein forms differently. These four deglycopeptides mapped to the proteins OMgp (3 
peptides), and Noelin (1 peptide). OMgp is a CNS localized membrane glycoprotein ligand 
for the Nogo receptor, a so-called myelin-associated inhibitor (reviewed in 114). It has been 
demonstrated to be an important negative regulator for neurite growth 115, 116. Noelin is a 
secreted glycoprotein expressed in neurogenic tissues during development and interestingly, it 
has also been linked to the Nogo receptor through a study launching Noelin as a ligand for the 
Nogo A receptor 1 117. The Nogo receptor is known to limit the recovery from neural injury 
and neural plasticity as is reviewed in 118. Our deglycopeptide regulation data therefore 
suggest a shift in glycosylation status in RRMS patients of these two proteins that both serve 
as ligands to the Nogo receptor. It would be interesting to further explore how this affects the 
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Nogo receptor and possibly neuron growth and myelination, important CNS processes known 
to be affected in MS.  
To validate our glycosylation data and further investigate if glycosylation status is in 
fact altered in the RRMS pathology, we envision applying methods for true site-specific 
glycoproteomics where the intact glycopeptide is analyzed by tandem mass spectrometry. 
This has already been investigated and applied for CSF by a few research groups, presenting 
data for the major CSF glycoproteins 111, 113, 119, and relevant aspects of glycoproteomics have 
also been reviewed 120-122. However the methods for intact glycopeptide analysis are still not 




This study presents an in-depth analysis of the CSF proteome, comparing RRMS patients and 
neurological controls, and reports the largest set of quantified proteins and deglycopeptides in 
CSF to date. Pathway analyses of significantly changed proteins between the compared 
groups highlight biological processes that can be linked to MS pathology like inflammation, 
ECM organization, cell adhesion, immune system processes and neuron development. Of the 
clusters of changed proteins, cadherins, collagens, complement and proteoglycans were 
among those that appeared from the analysis, and these can also to a large degree be linked to 
the biological processes found changed. The correlating information from the pathway and 
cluster analysis gives a deep insight into the CNS processes affected by RRMS reflected in 
the CSF proteome. Many disease specific changes found among the deglycopeptides where 
the global protein abundance was not affected indicate that glycosylation status is affected by 
MS, and this group of proteins reveals a new level of information in the CNS pathology. Our 
study confirms many of the previously observed proteins changed by RRMS, but also reveals 
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AD Alzheimer’s disease  
AGC automatic gain control  
APP amyloid-beta A4 protein  
BBB blood-brain-barrier  
CDMS clinically definite multiple sclerosis 
CHI3L1 chitinase-3-like protein 1 
CHI3L2 chitinase-3-like protein 2 
CIS clinically isolated syndrome 
CNS central nervous system 
CSF cerebrospinal fluid 
DTT dithiothreitol 
ECM extracellular  matrix 
EDSS expanded disability status scale 
EGFR epidermal growth factor receptor 
FA formic acid 
FC fold change 
FDR false discovery rate 
GO gene ontology 
HCD higher energy collision dissociation  
IAA iodoacetamide 
Ig immunoglobulin 
IT injection time 
LP lumbar puncture 
MRI magnetic resonance imaging 
MS multiple sclerosis 
NFL neurofilament light polypeptide  
NOG N-Octyl-β-D-glucopyranoside 
OCB oligoclonal band 
OMgp oligo-myelin glycoprotein  
OND other neurological disease  
PD Parkinson’s disease  
PG proteoglycan 
PNGase F peptide -N-Glycosidase F 
PPI protein-protein interaction  
RRMS relapsing-remitting multiple sclerosis 
TMT tandem mass tag 




Supplemental Information. Categorization of significant deglycopeptides, literature data 
inclusion criteria and categorization of literature studies. 
Table S1. Detailed information for the patients and controls included in the CSF pools. 
RRMS patients are in sheet A and controls in sheet B. This table also indicates which of the 
included samples that have been used by our group in previous studies. 
Table S2. LC-gradient and peptide fraction collection information. 
Table S3. LC-gradient for LC-MS/MS analysis for the global data and the glycoproteome 
data. 
Table S4. Data from the global proteome analysis. Default protein export from Reporter 
(sheet A), and all quantified proteins (sheet B).  
Table S5. Data from the glycoproteome analysis. Default peptide export (sheet A), all 
quantified peptides (sheet B), all deglycopeptides (sheet C), all high confident 
deglycopeptides (sheet D), all deglycopeptides with significant p-value (sheet E), all 
deglycopeptides with significant p-value and z-score (sheet F), all category 1 significant 
deglycopeptides (sheet G) and all deglycopeptides also found as non-glycosylated in the 
global dataset (sheet H).  
Table S6: 484 significant proteins from the global proteome analysis (sheet A). Sheet A also 
indicates which of the significant proteins that previously have been found in serum/plasma. 
The proteins included in the STRING network and in the ClueGO analysis is shown in sheet 
B.  
Table S7. 49 category 1 deglycopeptides with significant p-value and z-score. 
Table S8. Comparison of fold change deglycopeptides vs. global protein. . Details for 
significant peptide/protein comparison (sheet A), comparison plot significant peptide/protein 
comparison (sheet B), details for all peptide/protein comparison (sheet A), comparison plot all 
peptide/protein comparison (sheet B). 
Table S9. Enriched biological processes in ClueGO. Global data.  
Table S10. Enriched biological processes in ClueGO. Glycoproteome data.  
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LIST OF FIGURE LEGENDS 
Figure 1. Illustration of the pooling procedure (A) and the workflow of global (B) and deglycoproteome 
(C) experiments performed in this study. The pooling procedure shown in Figure 1A illustrates that 21 
relapsing-remitting multiple sclerosis (RRMS) patients and 21 neurological controls with other neurological 
diseases (OND) were separated into six pools, with seven individuals in each pool. These pools were used for 
two separate experiments: B) Global proteome analysis and C) Deglycoproteome analysis. Only the global 
experiment included protein depletion (B), while trypsin digestion, TMT labeling and combination of the labeled 
pools was common for both experiments. Glycopeptide capture by solid-phase enrichment of N-linked 
glycopeptides (SPEG) was then performed in the glycoproteome experiment (C), followed by peptide 
fractionation, LC-MS/MS analysis and protein and peptide identification and quantification, which was common 
for both experiments. 
 
Figure 2: Distribution of protein data for proteins previously quantified in comparable CSF studies. 
Proteins found significantly increased (left) or decreased (right) in MS were compared separately to eight 
publications. Red circles represent the query proteins found increased in MS compared to Non-MS in 100% of 
the studies and pink circles represent the proteins found increased in MS in the majority of studies, but with  
some conflicting data. Green and light green circles represent these same trends for the decreased proteins. The 
blue circles represent the proteins found unaltered between MS and Non-MS on average in the seven studies.  
The MS category is a combination of the reported MS subcategories: RRMS, CDMS and CIS with conversion to 
MS, and the Non-MS category is a combination of the control group subcategories reported as OND, 
Symptomatic controls and Non-MS. More information about this categorization is in Supplemental 
Information. * Combined categories.     
   
Figure 3. Biological processes GO enriched in proteins increased (A and B) and decreased (C and D) in 
CSF of RRMS patients. The global data is shown in A (increased in RRMS) and C (decreased in RRMS) and 
the glycoproteome data is shown in B (increased in RRMS) and D (decreased in RRMS).  
 
Figure 4. Protein-protein interaction (PPI) network. 484 significantly changed proteins between the RRMS 
patients and the controls (Table S6) were imported into STRING 45 and interactions were found between 222 of 
the 484 proteins. The PPI was visualized in Cytoscape v3.3.0. Green and red colors represent lower and higher 
expression of proteins in CSF between RRMS patients and controls, respectively. Light green and light red 
represent proteins with z-score significance > 0.05, while the dark green and red proteins have z-score 
significance < 0.05. Rectangles are proteins with a t-test p-value < 0.01, while the proteins represented by a 
circle have p-value between 0.01 and 0.05.  
 
Figure 5. Cluster analysis of the protein-protein interaction network using ClusterONE. A minimum of 
five genes was included in the network and interaction evidence towards the combined score from STRING. a) 
cadherins b) collagens c) complement proteins d) ephrins and proteins involved in synaptic plasticity e) proteins 
involved in aminoglycan processes f) proteins involved in the coagulation and inflammation. Green and red 
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colors represent lower and higher expression of proteins in CSF between RRMS patients and controls, 
respectively. Light green and light red represent proteins with z-score significance > 0.05, while the dark green 
and red proteins have z-score significance < 0.05. Rectangles are proteins with a t-test p-value < 0.01 while the 
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